ClinicalTrials.gg

Program

pozelimab

Also written as “Pozelimab”, “REGN3918” and “Pozelimab + Cemdisiran”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Geographic Atrophy, led by Regeneron Pharmaceuticals.

Furthest: phase 4, since Aug 19, 202514 company-led studies, 5 open or runningNext primary completion: Jul 3, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals145 open or runningphase 4since Aug 19, 2025Apr 5, 2017Jul 3, 2028phase 1 · NCT07230834

Also a collaborator on its studies: Alnylam Pharmaceuticals.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 5, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03115996 · 56 enrolled · United Kingdom
  2. May 8, 2019Phase 2 study in Hemoglobinuria, ParoxysmalNCT03946748 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
  3. Nov 11, 2019Phase 3 study in Hemoglobinuria, ParoxysmalNCT04162470 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
  4. Dec 20, 2019Phase 3 study in Protein-Losing EnteropathiesNCT04209634 · 10 enrolled · United States, Thailand, Turkey (Türkiye)
  5. Jul 13, 2020Phase 1 study in Healthy VolunteerNCT04491838 · 40 enrolled · Belgium
  6. Oct 21, 2020Phase 1 study in HealthyNCT04601844 · 19 enrolled · Belgium
  7. Mar 19, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04811716 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
  8. Apr 23, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04888507 · 6 enrolled · United Kingdom
  9. Jun 17, 2021Phase 1 study in HealthyNCT04940364 · 30 enrolled · United Kingdom
  10. Sep 27, 2021Phase 3 study in Myasthenia GravisNCT05070858 · 288 enrolled · United States, Belgium, Brazil and more
  11. Feb 6, 2023Phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921 · 202 planned · Brazil, Canada, Colombia and more
  12. Aug 13, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745 · 35 planned · Brazil, Canada, Italy and more
  13. Aug 19, 2025Phase 4 study in Protein-Losing EnteropathiesNCT07142343 · 5 planned · Turkey (Türkiye)
  14. Nov 13, 2025Phase 1 study in Geographic AtrophyNCT07230834 · 54 planned · United States, Georgia, Puerto Rico and more

Ahead

  1. Jul 3, 2028Primary completion: phase 1 study in Geographic AtrophyNCT07230834
  2. Oct 10, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921
  3. Jan 18, 2030Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745
  4. Feb 12, 2030Primary completion: phase 4 study in Protein-Losing EnteropathiesNCT07142343

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230834Geographic Atrophy · United States, Georgia, Puerto Rico and more1RecruitingJul 3, 202854
NCT07142343Protein-Losing Enteropathies · Turkey (Türkiye)4RecruitingFeb 12, 20305
NCT07154745Hemoglobinuria, Paroxysmal · Brazil, Canada, Italy and more3RecruitingJan 18, 203035
NCT05744921Hemoglobinuria, Paroxysmal · Brazil, Canada, Colombia and more3RecruitingOct 10, 2028202
NCT05070858Myasthenia Gravis · United States, Belgium, Brazil and more3Active, not recruitingJul 8, 2025288
NCT04940364Healthy · United Kingdom1CompletedJun 22, 202230
NCT04888507Hemoglobinuria, Paroxysmal · United Kingdom2CompletedMay 5, 20226
NCT04811716Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more2CompletedOct 25, 202224
NCT04601844Healthy · Belgium1CompletedJul 23, 202119
NCT04491838Healthy Volunteer · Belgium1CompletedMar 5, 202140
NCT04209634Protein-Losing Enteropathies · United States, Thailand, Turkey (Türkiye)3CompletedNov 9, 202110
NCT04162470Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more3TerminatedApr 7, 202224
NCT03946748Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more2CompletedJun 9, 202124
NCT03115996Healthy Volunteers · United Kingdom1CompletedAug 31, 201856

How it is read

Names in the registry

  • “Pozelimab”, 10 entries
  • “REGN3918”, 3 entries
  • “Pozelimab + Cemdisiran”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.